Equities research analysts predict that GlycoMimetics Inc (NASDAQ:GLYC) will report ($0.26) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for GlycoMimetics’ earnings, with the lowest EPS estimate coming in at ($0.27) and the highest estimate coming in at ($0.25). GlycoMimetics posted earnings per share of ($0.36) during the same quarter last year, which indicates a positive year over year growth rate of 27.8%. The business is expected to issue its next earnings results on Wednesday, March 7th.
On average, analysts expect that GlycoMimetics will report full year earnings of ($1.12) per share for the current financial year, with EPS estimates ranging from ($1.15) to ($1.11). For the next financial year, analysts anticipate that the company will post earnings of ($0.86) per share, with EPS estimates ranging from ($1.73) to $0.34. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover GlycoMimetics.
GLYC has been the subject of several research analyst reports. Jefferies Group reiterated a “buy” rating and issued a $16.00 price objective on shares of GlycoMimetics in a research report on Thursday, October 26th. Zacks Investment Research downgraded GlycoMimetics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. BidaskClub upgraded GlycoMimetics from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Roth Capital set a $35.00 price objective on GlycoMimetics and gave the company a “buy” rating in a research report on Thursday, February 8th. Finally, Cowen reiterated a “buy” rating on shares of GlycoMimetics in a research report on Wednesday, December 6th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $22.67.
In other news, SVP Helen M. Thackray sold 2,000 shares of GlycoMimetics stock in a transaction on Friday, December 8th. The stock was sold at an average price of $15.01, for a total value of $30,020.00. Following the completion of the sale, the senior vice president now directly owns 148,615 shares of the company’s stock, valued at approximately $2,230,711.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 43.80% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in shares of GlycoMimetics in the 4th quarter valued at $103,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of GlycoMimetics in the 2nd quarter valued at $146,000. Paloma Partners Management Co acquired a new stake in shares of GlycoMimetics in the 4th quarter valued at $170,000. Fox Run Management L.L.C. acquired a new stake in shares of GlycoMimetics in the 3rd quarter valued at $173,000. Finally, First Mercantile Trust Co. increased its stake in shares of GlycoMimetics by 26.6% in the 4th quarter. First Mercantile Trust Co. now owns 11,726 shares of the biotechnology company’s stock valued at $197,000 after buying an additional 2,466 shares during the period. 97.44% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “-$0.26 EPS Expected for GlycoMimetics Inc (GLYC) This Quarter” was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://weekherald.com/2018/02/23/0-26-eps-expected-for-glycomimetics-inc-glyc-this-quarter.html.
GlycoMimetics Company Profile
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.